Zydus Lifesciences' North American market sales see strong growth, profit surges unexpectedly
Special Topic: Focus on US Stock Market Q4 2025 Financial Reports
On Monday, Indian pharmaceutical company Zydus Lifesciences Ltd released its financial report, showing that third-quarter profits exceeded market expectations, driven by the launch of new drugs in its largest market, North America.
For the quarter ended December 31, the company reported consolidated profits of 10.42 billion Indian rupees (approximately $115.1 million), up from 10.24 billion Indian rupees in the same period last year.
According to data compiled by London Stock Exchange Group, analysts had previously expected the company’s quarterly profit to decline to 9.32 billion Indian rupees.
The company’s overall revenue increased by 30.3% year-on-year, mainly owing to a 16.4% rise in North American sales and a nearly 13% growth in sales in the domestic Indian market.
Core Background
For most Indian generic drug companies, including Zydus Lifesciences, a majority of their revenue comes from the US market. However, these companies are facing pricing pressures due to intense market competition.
Since early 2025, the launch of new drugs—especially those in Zydus’s specialty drug pipeline—has driven the company’s growth in the US market. During this financial reporting period, the company added four new products to the market.
Meanwhile, Zydus’s peers Cipla and Dr. Reddy’s Laboratories both reported sluggish US sales during the same quarter.
Peer Comparison (Next 12-Month Forecast)
Table
| Zydus Lifesciences Ltd | 14.34 | 7.15 | -10.25 | Hold | 29 | 0.88 | 1.24 |
| Alkem Laboratories Ltd | 12.31 | 10.68 | 22.55 | Buy | 11 | 0.81 | 1.38 |
| Dr. Reddy’s Laboratories Ltd | 13.22 | 3.29 | -10.23 | Hold | 39 | 0.93 | 0.64 |
| Cipla Ltd | 15.09 | 7.85 | 0.62 | Hold | 37 | 0.91 | 0.98 |
* Average Analyst Rating: Standardized average based on the rankings “Strong Buy, Buy, Hold, Sell, Strong Sell”
** Price-to-Target Ratio: The ratio of the latest closing price to the average analyst target price. A value above 1 indicates the current stock price is above the target price.
Stock Performance from October to December
Note: All data comes from London Stock Exchange Group
Exchange rate conversion: 1 USD = 90.5590 Indian rupees
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tonight, a "dovish rate hike"?
The Federal Reserve is almost certain to raise interest rates tonight, but the key issue is "what will be said after the hike." Citi characterizes this move as a "fine-tuning" adjustment, suggesting there is no inevitable future rate hike, yet warns that if Chairman Powell does not provide clear forward guidance, it will trigger significant market volatility. Goldman Sachs bluntly stated that there is insufficient economic foundation for this rate hike, with inflation being merely a one-off factor, and expects this to be a "signal-less rate hike."
JPMorgan: "Open source disruption" and "AI safety" are not issues, there is still room for capital expenditure in the next two years, semiconductor equipment will become the "new bottleneck"
JPMorgan believes that open-source models are not a threat, regulatory disruptions are only short-term, and cloud vendors’ leverage remains low—the fundamentals of computing power investment have not changed. It forecasts that the capital expenditure of the seven major tech giants will soar from $443 billion in 2025 to $1.577 trillion in 2027, with semiconductor equipment becoming the core bottleneck of the supply chain and a new round of price increases expected in wafer foundry and advanced packaging.
Micron executive: Storage determines AI limits, substantial new capacity will come after 2028
Micron executive Sumit Sadana stated that memory bandwidth and capacity have become the core factors determining the performance ceiling of AI systems. In the face of structural imbalances between supply and demand, Micron expects to increase capital expenditure to over $45 billion in fiscal year 2027, but due to process complexity, substantive new capacity will not be released until 2028. Additionally, long-term supply agreements are reshaping the industry's business model, and humanoid robots will trigger the next wave of massive demand.
Goldman Sachs warns top clients: AI momentum trading shows unprecedented cracks, recommends hedging
Goldman Sachs has issued a rare warning to top clients: deep structural cracks are emerging in AI momentum. The AI-themed basket has dropped nearly 45% from its peak, with the one-day performance gap between short-term and long-term momentum reaching a five-year high. Capital is accelerating its shift from semiconductors to software. Goldman Sachs explicitly recommends that investors with AI exposure start hedging.
Crypto prices
More
